Skip to content
Catalyst

PapersPMID:22894890

Chamomile (Matricaria recutita) may provide antidepressant activity in anxious, depressed humans: an exploratory study.

Alternative therapies in health and medicine2012The record ↗

  1. Finding, moderate evidencelowersHamilton Depression Rating Scale (HDRS) total score

What moved

1 findingHow to read these marks →
  • “After controlling for baseline values, we observed a significantly greater reduction over time in total HAM-D scores for chamomile versus placebo in all subjects (p<0.05).”
    Study
    RCT
    Duration
    8 weeks
    Dose studied
    220 mg capsules, 1 daily in week 1, 2 daily in week 2, titrated by HAM-A response to up to 5 daily (1100 mg/day) in weeks 5-8
    Population
    adults with mild to moderate generalized anxiety disorder (DSM-IV), some with comorbid or past depression; exploratory reanalysis of a randomized placebo-controlled trial

Study record

Design
randomised controlled trial
Species
human
Population
Outpatients with mild to moderate generalized anxiety disorder (exploratory reanalysis of the 2009 chamomile trial), with subgroups of current co-morbid depression, past depression, and no current or past depression
Participants
57
Comparator
placebo
Duration
56 days
Endpoints measured
7